In Vitro Activity of Nemonoxacin, a Novel Nonfluorinated Quinolone, against 2,440 Clinical Isolates-Reference-Cited by-同舟云学术

In Vitro Activity of Nemonoxacin, a Novel Nonfluorinated Quinolone, against 2,440 Clinical Isolates

Published:2009-11 Issue:11 Volume:53 Page:4915-4920
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Adam Heather J.¹,Laing Nancy M.²,King C. Richard³,Lulashnyk Ben²,Hoban Daryl J.¹²,Zhanel George G.²

Affiliation:

1. Diagnostic Services of Manitoba/Department of Clinical Microbiology, Health Sciences Centre, Winnipeg, Manitoba, Canada

2. Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

3. TaiGen Biotechnology Co. Ltd., Taipei, Taiwan

Abstract

ABSTRACT The in vitro activity of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, was tested against 2,440 clinical isolates. Nemonoxacin was at least fourfold more active than levofloxacin and moxifloxacin against most gram-positive cocci tested (shown by the following MIC 90 /range [μg/ml] values; community-associated methicillin [meticillin]-resistant Staphylococcus aureus , 0.5/0.015 to 2; Staphylococcus epidermidis , 0.5/0.015 to 4 for methicillin-susceptible staphylococci and 2/0.12 to 2 for methicillin-resistant staphylococci; Streptococcus pneumoniae , 0.015/≤0.008 to 0.25; Enterococcus faecalis , 1/0.03 to 128). Nemonoxacin activity against gram-negative bacilli was similar to levofloxacin and moxifloxacin (MIC 90 /range [μg/ml]; Escherichia coli , 32/≤0.015 to ≥512; Klebsiella pneumoniae , 2/≤0.015 to 128; K . oxytoca , 0.5/0.06 to 1; Proteus mirabilis , 16/0.25 to ≥512; Pseudomonas aeruginosa , 32/≤0.015 to ≥512; Acinetobacter baumannii , 1/0.12 to 16).

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00078-09

Reference18 articles.

1. Andersson, M. I., and A. P. MacGowan. 2003. Development of the quinolones. J. Antimicrob. Chemother.51(Suppl. 1):1-11.

2. In Vitro Activities of Three Nonfluorinated Quinolones against Representative Bacterial Isolates

3. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically 2006

4. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing. Eighteenth informational supplement. M100-S18. Clinical and Laboratory Standards Institute Wayne PA.

5. Golding, G., J. Campbell, D. Spreitzer, J. Veyhl, K. Surynicz, and A. Simor. 2008. A preliminary guideline for the assignment of methicillin-resistant Staphylococcus aureus to a Canadian pulsed-field gel electrophoresis epidemic type using spa typing. Can. J. Infect. Dis. Med. Microbiol.19:273-281.

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multicentre, randomised, double-blind, double-dummy, parallel-controlled, phase 3 clinical trial assessing the efficacy and safety of intravenous nemonoxacin malate vs. levofloxacin for community-acquired pneumonia in adult patients;International Journal of Antimicrobial Agents;2024-08

2. Treatment of MRSA Infection: Where are We?;Current Medicinal Chemistry;2024-08

3. Continuous flow process optimization aided by machine learning for a pharmaceutical intermediate;Journal of Flow Chemistry;2024-05-13

4. Nemonoxacin achieved a better symptomatic improvement and a prolonged interval to next exacerbation than moxifloxacin for outpatients with acute exacerbations of chronic obstructive pulmonary disease;Scientific Reports;2023-10-07

5. Staph wars: the antibiotic pipeline strikes back;Microbiology;2023-09-01